Funding for this research was provided by:
Foundation for the National Institutes of Health (HG008935, GM113194, T32GM007281)
National Cancer Institute (CA253987)
Received: 28 April 2022
Accepted: 19 January 2023
First Online: 24 January 2023
: Ethics approvals are not applicable for this study.
: C.H. is a scientific founder and a scientific advisory board member of Accent Therapeutics, Inc., Aferna Green. Inc., and AccuraDX Inc. The other authors declare no competing interests.